Go Back

AliveCor Data Yield Reaches 25MM ECGs Largest Data Set of Any Consumer ECG Device

Mountain View, Calif. – April 5, 2018

AliveCor Kardia Platform now Adopted by World’s Leading Provider of Blood Pressure Devices

AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, announced today that it had surpassed the milestone of 25 million recorded ECGs – by far the largest data set ever collected by any consumer ECG. The company also announced that its KardiaBand product, paired with Apple Watch, had successfully recorded more than a century of photoplethysmography (PPG) data simultaneously with contemporaneous ECG, a potential treasure trove of uniquely labeled data for use in artificial intelligence based systems.

“As our data yield expands, and the pace of collection quickens, our ability to achieve our mission of ‘seeing the invisible,’ and fundamentally changing the quality of heart care becomes more and more tangible” said Vic Gundotra, CEO of AliveCor.

Simultaneous with this announcement, AliveCor announced the deployment of its multi-device Kardia app platform to Omron Healthcare, the world’s leading manufacturer of home blood pressure monitors. Starting this week, Kardia technology will provide the new mobile interface for Omron’s globally ubiquitous blood pressure devices.

The new Omron Connect App – powered by AliveCor – can collect a range of critical risk factor data collected by connected devices, including blood pressure, ECG, heart rate, weight, and medication intake. Critically, it allows users to easily store, track and share this information with doctors and caregivers.

“By providing the technology behind the new Omron Connect app, AliveCor will positively impact millions of additional lives with advanced heart health capabilities and serve as the default medical platform for one of today’s most innovative health companies,” said Gundotra.

The need for more accessible, high-quality heart health data is vital. Up to six million Americans have atrial fibrillation, and over 100 million Americans have high blood pressure, both leading causes of stroke. Now, with the AliveCor and Omron partnership, patients and physicians have the unprecedented ability to monitor these two major risk factors in tandem.

About AliveCor

AliveCor, Inc. is pioneering the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is the most clinically validated mobile ECG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG. Kardia is the first A.I. enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. KardiaBand is the first FDA-cleared medical device accessory for Apple Watch. AliveCor was named the No.1 artificial intelligence company on Fast Company's Top 50 Most Innovative Companies, in addition to ranking 20th overall in an evaluation of thousands of companies worldwide. AliveCor is a privately-held company headquartered in Mountain View, Calif. For more information, visit alivecor.com.

Most Recent

November 10, 2023

AliveCor Appoints Michael Rolla as Chief Revenue Officer, Enterprise

Read More

September 27, 2023

AliveCor's KardiaMobile® 6L Becomes First Personal ECG Device Recommended for Use in Psychiatric Services in England and Wales

Read More

July 26, 2023

AliveCor and Thomas Jefferson University Hospital Partner to Evaluate KardiaMobile 6L for QT Prolongation Screening in Patients Treated for Opioid Use Disorder

Read More

Let's transform cardiovascular care together

If you are an employer or payer looking for a comprehensive heart health enterprise solution, contact us.